INITIATIVE ON METHODS, MEASUREMENT, AND PAIN ASSESSMENT IN CLINICAL TRIALS

IMMPACT-XVI

RECOMMENDATIONS FOR PATIENT PHENOTYPING IN PHASE 2 AND 3 ANALGESIC CLINICAL TRIALS

JUNE 14-15, 2013

SOFITEL
WASHINGTON, DC

THURSDAY, JUNE 13

7:00 PM RECEPTION AND DINNER (at the Westin)

FRIDAY, JUNE 14

7:30–8:00 AM CONTINENTAL BREAKFAST

8:00–8:30 AM Welcome and introductions
  • Dennis Turk, PhD

8:30–9:15 AM Patient-reported pain and symptom measures, including psychological and sleep measures for Phase 2 and 3 trials
  • Robert Edwards, PhD

9:15–9:45 AM PROMIS measures and the NIH tool box for Phase 2 and 3 trials
  • Raymond Dionne, DDS, PhD

9:45–10:15 AM COFFEE BREAK

10:15–12:15 PM Panel discussion and Q & A on patient-reported measures for Phase 2 and 3 trials
  • moderator: Dennis Turk
  • Laurie Burke, RPh, MPH; Ray Dionne; Rob Edwards; Roger Fillingim, PhD; Ajay Wasan, MD

12:15–1:15 PM LUNCH

1:15–2:00 PM Quantitative sensory testing (QST) for Phase 2 trials
  • Per Hansson, MD, PhD

2:00–2:30 PM Conditioned pain modulation (CPM) / descending noxious inhibitory controls (DNIC) for Phase 2 and 3 trials
  • Simon Haroutunian, PharmD

2:30–3:00 PM COFFEE BREAK

3:00–5:00 PM Panel discussion and Q & A on QST and CPM/DNIC for Phase 2 trials
SATURDAY, JUNE 15

7:00–9:00 PM DINNER

7:30–8:00 AM CONTINENTAL BREAKFAST

8:00–8:45 AM Response to pharmacologic challenge in Phase 2 and 3 trials
  • Martin Angst, MD

8:45–9:30 AM Clinical testing and QST in Phase 3 trials
  • Roy Freeman, MD

9:30–10:00 AM COFFEE BREAK

10:00–12:00 PM Panel discussion and Q & A on pharmacologic challenge, clinical testing, and QST in Phase 3 trials
  • moderator: Nathaniel Katz, MD
  • Martin Angst; Roy Freeman; Bob Rappaport, MD; Joachim Scholz, MD; David Yarnitsky, MD

12:00–1:00 PM LUNCH

1:00–4:00 PM Group discussion: consensus recommendations for patient phenotyping in Phase 2 and 3 analgesic trials
  • moderators: Bob Dworkin and Dennis Turk
  • with continuous coffee service